Michael Anstey
Partner at Cambridge Innovation Capital
Cambridge, England
Overview
Work Experience
Partner
2017 - Current
Cambridge Innovation Capital backs world-leading life sciences and deep tech companies with a connection to Cambridge UK, Europe’s leading innovation ecosystem. As a preferred investor for the University of Cambridge, we have unparalleled access to investment opportunities in the ecosystem. Since our inception in 2013, we have raised over £500 million to invest in disruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health and genomics/proteomics.
Board Observer
2024
Nuclera is the pioneer in bringing rapid protein prototyping to the benchtop. The eProtein Discovery platform enables users to go from DNA to protein in less than 48 hours, empowering researchers with easy access to target proteins and accelerating breakthrough improvements in human health
Board Member
2022
Immutrin is developing novel therapies to treat a class of devastating rare diseases called systemic and local amyloidosis
Board Member
2022
Innovate Cambridge was launched in September 2022 to define the future of the Greater Cambridge life sciences and technology ecosystem to ensure it continues to transform the UK and the world for the better
Board Member
2021
Epitopea is developing accessible "off-the-shelf" cancer immunotherapies that will deliver durable benefits. To achieve this, the company is exploiting a novel class of untapped tumour-specific antigens (TSAs), Cryptigen TSAs, designed to treat a broad patient population.
Board Member
2019
Start Codon identifies and recruits high potential life science and healthcare companies from across the UK and beyond, provides seed-funding, and leverages the world-class resources of the Cambridge ecosystem to reduce risk and prepare them for a successful Series A fundraise.
Board Member
2018
Congenica is a digital health company enabling genomic medicine with the world’s leading clinical decision support platform for the interpretation of complex genomic data.
Board Member
2018 - 2023
STORM Therapeutics is the leading company tackling disease through modulating RNA modifying enzymes and is developing a unique platform and pipeline to address these enzyme classes, including RNA methyltransferases.
Board Member
2017 - 2020
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles®, for diseases that are underserved by existing therapeutics. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA.
Co-Founder
2014 - 2018
Proteorex is a biotechnology company developing small molecule therapeutics that target protein-protein interactions implicated in disease.
Education
DPhil
2003 - 2007
First Class BSc(Hons)
1999 - 2003